iBio Appoints Robert M. Lutz as Chief Financial & Business Officer
February 16, 2021 08:00 ET
|
iBio, Inc.
BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the...
iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
February 09, 2021 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will...
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
December 28, 2020 07:30 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the...
iBio Announces Closing of its Public Offering of Common Stock
December 10, 2020 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing...
iBio Announces Pricing of $35 Million Public Offering of Common Stock
December 08, 2020 08:55 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing...
iBio Announces Proposed Public Offering of Common Stock
December 07, 2020 16:01 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an...
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
December 01, 2020 16:30 ET
|
iBio, Inc.
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”),...
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
November 24, 2020 07:30 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the...
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update
November 16, 2020 16:05 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its...
iBio to Participate in Alliance Global Partners’ Virtual Healthcare Symposium
November 12, 2020 08:00 ET
|
iBio, Inc.
BRYAN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that...